{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:24:01Z","timestamp":1740144241988,"version":"3.37.3"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Project of Heilongjiang Provincial Department of Health","award":["2013257"],"award-info":[{"award-number":["2013257"]}]},{"name":"Jiamusi University Project","award":["13Z1201547"],"award-info":[{"award-number":["13Z1201547"]}]},{"name":"Scientific Research Projects of Heilongjiang Provincial Health and Health Committee","award":["2019-327"],"award-info":[{"award-number":["2019-327"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Bimatoprost has been reported to treat primary open-angle glaucoma (POAG) effectively. However, up-to-date, no systematic review has specifically addressed the efficacy and safety of bimatoprost for the treatment of POAG. Therefore, this study will propose to appraise the efficacy and safety of bimatoprost for the treatment of POAG.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We will perform a systematic search in MEDLINE, EMBASE, CINAHI, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Web of Science, Cochrane Library, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure from inception up to the March 1, 2020. We will include randomized controlled trials (RCTs) for evaluating the efficacy and safety of bimatoprost for the treatment of POAG. Primary outcome is the mean intraocular pressure (IOP) reduction from baseline to the endpoint, and change in best corrected visual acuity. Secondary outcomes are contrast sensitivity, rate of progression of glaucoma, quality of life, and incidence of adverse events. Study quality will be examined by Cochrane Collaboration tool, and strength of evidence will be evaluated by Grading of Recommendations Assessment Development and Evaluation tool.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This proposed study will outline the current RCTs to assess the efficacy and safety of bimatoprost for the treatment of POAG.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The findings of this study will confirm whether bimatoprost is beneficial to patients with POAG.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Systematic review registration:<\/jats:title>\n            <jats:p>INPLASY202040118.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020356","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T20:02:39Z","timestamp":1591214559000},"page":"e20356","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of bimatoprost for the treatment of primary open-angle glaucoma"],"prefix":"10.1097","volume":"99","author":[{"given":"Hong-wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-tong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-bo","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-2876","authenticated-orcid":false,"given":"Yan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12886-015-0124-x","article-title":"Prevalence and risk factors of primary open-angle glaucoma in a city of Eastern China: a population-based study in Pudong New District, Shanghai","volume":"15","author":"He","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ophtha.2007.04.050","article-title":"Glaucoma and quality of life: the Salisbury Eye Evaluation","volume":"115","author":"Freeman","year":"2008","journal-title":"Ophthalmology"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.1167\/iovs.11-7472","article-title":"Prevalence of primary open angle glaucoma in a rural adult Chinese population: the Handan eye study","volume":"52","author":"Liang","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/OPTH.S103084","article-title":"Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice","volume":"10","author":"Pillunat","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R6-20230915","first-page":"82","article-title":"Mental disorders and quality of life of patients with primary open-angle glaucoma","volume":"107","author":"Kirillova","year":"2007","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1185\/03007990802111068","article-title":"Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries","volume":"24","author":"Thygesen","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1185\/030079905X65600","article-title":"Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma","volume":"21","author":"Holmstrom","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0161-6420(02)01891-2","article-title":"Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost","volume":"110","author":"Gandolfi","year":"2003","journal-title":"Ophthalmology"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ophtha.2004.08.022","article-title":"Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients","volume":"112","author":"Konstas","year":"2005","journal-title":"Ophthalmology"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/bjo.2004.053074","article-title":"Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomised clinical trial","volume":"89","author":"Doi","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jop.2006.0107","article-title":"Comparative evaluation of bimatoprost monotherapy in primary chronic angle closure and primary open angle glaucoma eyes: a three-year study","volume":"23","author":"Gupta","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1136\/bjo.2009.162859","article-title":"The additive effect of dorzolamide hydrochloride (Trusopt) and a morning dose of bimatoprost (Lumigan) on intraocular pressure and retrobulbar blood flow in patients with primary open-angle glaucoma","volume":"94","author":"Stankiewicz","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1111\/j.1755-3768.2010.02036.x","article-title":"Intraocular pressure and ocular hemodynamics in patients with primary open-angle glaucoma treated with the combination of morning dosing of bimatoprost and dorzolamide hydrochloride","volume":"89","author":"Stankiewicz","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3126\/nepjoph.v5i1.7831","article-title":"Comparison of the efficacy and safety of bimatoprost (0.03%) and travoprost (0.004%) in patients with primary open angle glaucoma","volume":"5","author":"Chander","year":"2013","journal-title":"Nepal J Ophthalmol"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3341\/kjo.2014.28.5.399","article-title":"Comparing the efficacy of latanoprost (0.005%), bimatoprost (0.03%), travoprost (0. 004%), and timolol (0. 5%) in the treatment of primary open angle glaucoma","volume":"28","author":"Mishra","year":"2014","journal-title":"Korean J Ophthalmol"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1471-2415-14-161","article-title":"Efficacy and tolerability of fixed-combination bimatoprost\/timolol versus fixed-combination dorzolamide\/brimonidine\/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study","volume":"14","author":"Garc\u00eda-L\u00f3pez","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.4103\/0301-4738.149134","article-title":"A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma\/ocular hypertension","volume":"62","author":"Natt","year":"2014","journal-title":"Indian J Ophthalmol"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:05:55Z","timestamp":1694822755000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020356"}},"subtitle":["A protocol of systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":21,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020356","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,6,5]]}}}